Cargando…
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical t...
Autores principales: | Pastick, Katelyn A, Okafor, Elizabeth C, Wang, Fan, Lofgren, Sarah M, Skipper, Caleb P, Nicol, Melanie R, Pullen, Matthew F, Rajasingham, Radha, McDonald, Emily G, Lee, Todd C, Schwartz, Ilan S, Kelly, Lauren E, Lother, Sylvain A, Mitjà, Oriol, Letang, Emili, Abassi, Mahsa, Boulware, David R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184359/ https://www.ncbi.nlm.nih.gov/pubmed/32363212 http://dx.doi.org/10.1093/ofid/ofaa130 |
Ejemplares similares
-
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
por: Boulware, David R., et al.
Publicado: (2020) -
Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19
por: Lofgren, Sarah M, et al.
Publicado: (2020) -
Symptoms of COVID-19 Outpatients in the United States
por: Pullen, Matthew F, et al.
Publicado: (2020) -
Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic
por: Pullen, Matthew F, et al.
Publicado: (2020) -
Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial
por: Lother, Sylvain A., et al.
Publicado: (2020)